Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Finding Even More New Reactions By Looking For them | Main | The XMRV Story Is Not Getting Any Saner »

November 30, 2011

Lipitor Expiration Day

Email This Entry

Posted by Derek

As one of Garrison Keillor's characters says (in WLT), "I always knew the end would come. And here it is, the end". Lipitor (atorvastatin) goes off patent today, and I can recommend this overview by Matthew Herper at Forbes. Will there ever be another drug like it? The people developing the CETP inhibitors hope so. . .

Comments (15) + TrackBacks (0) | Category: Cardiovascular Disease | Drug Industry History


COMMENTS

1. startup on November 30, 2011 1:44 PM writes...

I figured as much when on the way to work I heard Pfizer ad promising it for as low as $4/month.

Permalink to Comment

2. Biotechtranslated on November 30, 2011 1:55 PM writes...

I think the most interesting thing about the arrival of generic Lipitor is Pfizer's strategy so far. I can't even think of a time when a pharma company put this much effort into holding onto branded sales post LOE.

So far:
- discounts to PBMs to get preference to the generics (which seems to have caused a number of them to refuse to reimburse for the generic)
- co-pay assistance to make the out-of-pocket expenses for patients equal to the generics
- setting up a mail-order system so patients can get Lipitor directly from Pfizer

I think the next 6 months are going to be VERY interesting. Obviously Pfizer is pulling out the big guns on this one.

Mike

Permalink to Comment

3. NoDrugsNoJobs on November 30, 2011 1:55 PM writes...

Gonna go out on a limb and say the CETP inhibitors will never come close to the statins and for no other reason than we already have the statins - the baseline is moved so high with statin treatment that even if we see an additional benefit from CETP-inhibition, it is not going to be so dramatic and there will be additional side effects, and there is the cost, etc. I hope they really are as good as the lipid profiles they yield but would be very surprised if they are....but here's to hoping!

Permalink to Comment

4. Biotechtranslated on November 30, 2011 2:06 PM writes...

@#3,

From what I've read, CETP inhibitors aren't just going after the "improved lipid profile" but rather reversal of atherosclerosis similar to the apo A-1 milano therapy.

If they get that indication, then it wouldn't surprise me if they get bigger than the statins.

Mike

Permalink to Comment

5. pete on November 30, 2011 2:14 PM writes...

@3 NoDrugs
True. But with statin "resistance" running at roughly 20%, there's a sizable chunk of humanity that needs other therapeutic options. If shown to be effective & safe, newer CETPi could nonetheless add a lot of $imoleon$ to PharmaCo's bottom line.

Permalink to Comment

6. Curious Wavefunction on November 30, 2011 4:42 PM writes...

Another good quote for the company marketing Lipitor would have been "We have met the enemy and he is us".

Permalink to Comment

7. Anonymous on November 30, 2011 5:50 PM writes...

Well, we all know that Pfizer has been preparing for this day. They laid off so many scientists that I'm surprised anyone would even consider going there now or in the future.

Permalink to Comment

8. Chemjobber on November 30, 2011 7:19 PM writes...

I stood in a room in 2007 when outgoing PGRD chief John LaMattina said that Pfizer was right-sized for this day.

I wonder if JLM ever rues making that statement.

Permalink to Comment

9. Fred on November 30, 2011 7:31 PM writes...

Until the FDA is reformed and we get smart people in Pharma boardrooms, the drug industry isn't coming back. Read: never; it's cheaper to repackage existing products. If Vioxx isn't safe enough for the FDA, what hope do any of us have?

Permalink to Comment

10. Ricardo Rodriges on December 1, 2011 2:25 AM writes...

Unfortunately, I got some friend at the blue monster, really sorry for them. It seems like is worst there than at many other industries.

I was reading how Pfizer behave towards its employees over the 1929 depression, for a decade it made the concious decision to not lay off any employees, some companies should learn from their past.

Permalink to Comment

11. Morten G on December 1, 2011 9:54 AM writes...

I think maybe I'm confused about how atherosclerosis works.

LDL-particles oxidised -> taken up by macrophages -> foamy cells -> plaque, right?

How would messing with CETP improves this? Won't LDL particles simply become less stable if there's less cholesterol in them than nature intended?

Permalink to Comment

12. Vader on December 1, 2011 1:02 PM writes...

"If Vioxx isn't safe enough for the FDA, what hope do any of us have?"

Bears repeating. And repeating.

Permalink to Comment

13. Anonymous on December 2, 2011 7:26 AM writes...

Vioxx was save enough for the FDA, Merck decided it was not save enough for the public and pulled it. Hence the mess the industry is in now; the public doesn't trust the FDA and the FDA has raised the bar so high it's almost impossible to get new drugs approved, especially novel ones.

Permalink to Comment

14. Matthew Herper on December 2, 2011 7:42 AM writes...

CETP inhibitors: I didn't go through this for length reasons, but my basic argument would be that in order to be used for primary prevention, CETP inhibitors would have to work in quite a giant trial versus statins. In clinical trials, the event rate is already pretty low in those people. So even if they work very well, it's going to be hard to reach the market Lipitor reached with a CETP inhibitor.

More likely, with current market forces, they will be priced much higher than statins were and used mostly for secondary prevention.

Permalink to Comment

15. john calhoun on September 18, 2012 7:29 PM writes...

Derek, you're PRICELESS! Having read about hexanitrohexaazaisowurtzitane (CL-20), I annotated my copy with "a molecule just itching to become an explosion," and, noting its 3-D shape, "birdhouse-cum-boom." Like those? The worst TIWWW I ever handled was pyruvic acid, which, after I synthesized it, turned dark and suddenly ignited out the twin necks of my distilling flask to coat my lab partner with thousands of little curlicue carbon strings, which of course greatly endeared me to him. I also looked up chlorine trifluroride (ClF3) on Wiki and decided that I'd give anything that sets solid concrete on fire at least 100 megaparsecs of room to do its thing. I just finished John D. Clark's book 'Ignition! An informal history of liquid rocket propellants' and found out even more about all those hypergolic horrors that he researched for NASA, Thiokol, and other creators of deadly witches' brews. I highly recommend it, but I'll bet my last gram of Pu-239 you already have read it. Say, as a writer myself, I'll give you some free advice: Why not compile all those TIWWWs (and more) into a book? A hilarious tome like that might just make you enough money to pay for all those burn-ward stays you've no doubt accumulated--just reserve me an autographed copy and I'll call the whole thing even. Oh yes, I note that hexayaddayaddayadda even made it into Wiki on its own, so the people willing to fool with it are probably dwindling asymptotically to zero. I dropped out of that group as soon as I read your blurb.

Keep 'em coming, brother--you're one of the planet's true originals.

John Calhoun,
Fort Collins, CO

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Instructive Case of Galena Biopharma
Changes in Papers
InterMune Comes Through
For Immediate Rewording. Uh, Release.
ACS Webinars on Drug Discovery
Big Drug Mergers: So They're OK, Right?
Another Round of Stapled Peptide Wrangling
Ces3 (Ces1) Inhibition As a Drug Target